Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Characterisation of Glucose-Dependent Insulinotropic Polypeptide Receptor Antagonists in Rodent Pancreatic Beta Cells and Mice
R W Perry, S.R. Craig, MT Ng, et al.
Clinical Medicine Insights Endocrinology and Diabetes (2019) Vol. 12
Open Access | Times Cited: 19

Showing 19 citing articles:

The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets
Kimberley El, Jonathan D. Douros, Francis S. Willard, et al.
Nature Metabolism (2023) Vol. 5, Iss. 6, pp. 945-954
Open Access | Times Cited: 66
Glucose-dependent insulinotropic polypeptide (GIP)
Timo D. Müller, Alice E. Adriaenssens, Bo Ahrén, et al.
Molecular Metabolism (2025) Vol. 95, pp. 102118-102118
Open Access | Times Cited: 3
GLP-1/GIP analogs: potential impact in the landscape of obesity pharmacotherapy
Ryan A. Lafferty, Peter R. Flatt, Nigel Irwin
Expert Opinion on Pharmacotherapy (2023) Vol. 24, Iss. 5, pp. 587-597
Open Access | Times Cited: 31
Discovery of a potent GIPR peptide antagonist that is effective in rodent and human systems
Bin Yang, Vasily M. Gelfanov, Kimberley El, et al.
Molecular Metabolism (2022) Vol. 66, pp. 101638-101638
Open Access | Times Cited: 27
Blockade of gastric inhibitory polypeptide (GIP) action as a novel means of countering insulin resistance in the treatment of obesity-diabetes
Nigel Irwin, Victor A. Gault, Finbarr O’Harte, et al.
Peptides (2019) Vol. 125, pp. 170203-170203
Open Access | Times Cited: 20
Does GIPR blockade as well as agonism have a role to play in management of obesity and diabetes?
Ryan A. Lafferty, Peter R. Flatt, Victor A. Gault, et al.
Journal of Endocrinology (2024) Vol. 262, Iss. 2
Open Access | Times Cited: 2
Dose‐dependent efficacy of the glucose‐dependent insulinotropic polypeptide (GIP) receptor antagonist GIP(3‐30)NH2 on GIP actions in humans
Lærke S. Gasbjerg, Emilie Johanning Bari, Signe Stensen, et al.
Diabetes Obesity and Metabolism (2020) Vol. 23, Iss. 1, pp. 68-74
Closed Access | Times Cited: 18
Chronic peptide-based GIP receptor inhibition exhibits modest glucose metabolic changes in mice when administered either alone or combined with GLP-1 agonism
Jason A. West, Anastasia Tsakmaki, Soumitra S. Ghosh, et al.
PLoS ONE (2021) Vol. 16, Iss. 3, pp. e0249239-e0249239
Open Access | Times Cited: 14
Glucose‐dependent insulinotropic polypeptide receptor antagonist treatment causes a reduction in weight gain in ovariectomised high fat diet‐fed mice
Geke Aline Boer, Jenna Elizabeth Hunt, M Gabe, et al.
British Journal of Pharmacology (2022) Vol. 179, Iss. 18, pp. 4486-4499
Open Access | Times Cited: 9
GIP(3-30)NH2 – a tool for the study of GIP physiology
Mads Bank Lynggaard, Lærke S. Gasbjerg, Mikkel Christensen, et al.
Current Opinion in Pharmacology (2020) Vol. 55, pp. 31-40
Closed Access | Times Cited: 11
The dual incretin co-agonist tirzepatide increases both insulin secretion and glucose effectiveness in model experiments in mice
Giovanni Pacini, Bo Åhrén
Peptides (2023) Vol. 171, pp. 171117-171117
Open Access | Times Cited: 3
Human glucose-dependent insulinotropic polypeptide (GIP) is an antimicrobial adjuvant re-sensitising multidrug-resistant Gram-negative bacteria
Da’san M. M. Jaradat, Nehaya Al‐Karablieh, Basmah H. M. Zaarer, et al.
Biological Chemistry (2021) Vol. 402, Iss. 4, pp. 513-524
Closed Access | Times Cited: 7
Contribution of GIP and GLP-1 to the Insulin Response to Oral Administration of Glucose in Female Mice
Bo Åhrén
Biomedicines (2023) Vol. 11, Iss. 2, pp. 591-591
Open Access | Times Cited: 2
GLP-1 receptor agonism and GIP receptor antagonism induce substantial alterations in enteroendocrine and islet cell populations in obese high fat fed mice
Ananyaa Sridhar, Dawood Khan, Peter R. Flatt, et al.
Peptides (2023) Vol. 169, pp. 171093-171093
Open Access | Times Cited: 2
Therapeutic potentials of glucose-dependent insulinotropic polypeptide (GIP) in T2DM: Past, present, and future
Soumik Das, Harini Ravi, Achsha Babu, et al.
Advances in protein chemistry and structural biology (2024)
Closed Access
Peptide-based GIP receptor inhibition exhibits modest metabolic changes in mice when administered either alone or combined with GLP-1 agonism
Jason A. West, Soumitra S. Ghosh, David G. Parkes, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2019)
Open Access | Times Cited: 2
Incretin Analogues in the Therapy of Type 2 Diabetes and Obesity
Н. В. Булушова, I. A. Zalunin, A. S. Asrarkulova, et al.
Applied Biochemistry and Microbiology (2022) Vol. 58, Iss. 7, pp. 854-863
Closed Access | Times Cited: 1
Pharmacology of Gut Hormone Mimetics for Obesity and Diabetes
Ryan A. Lafferty, Finbarr O’Harte, Nigel Irwin, et al.
Elsevier eBooks (2021), pp. 301-343
Closed Access | Times Cited: 1
Incretin Analogues in Therapy of Type 2 Diabetes and Obesity
I. A. Zalunin, A. S. Asrarkulova, Д. Г. Козлов
Biotekhnologiya (2021) Vol. 37, Iss. 3, pp. 53-64
Closed Access | Times Cited: 1
Page 1

Scroll to top